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Ulcerative colitis in Taiwan: A potentially rising burdenInflammatory bowel disease (IBD), including ulcerative
colitis (UC), and Crohn disease generally first afflict patients as
young adults and persist as chronic conditions throughout their
lifetimes. In Asia (excluding Australia and New Zealand), IBD
is relatively uncommon, although UC is more prevalent than
Crohn disease. However, recent literature has shown that IBD is
increasing in incidence inmany parts of theAsia Pacific region.1
Using UC as an example, its incidence in Japan was reported to
be five in 100,000 individuals in 1974, increasing to 20 per
100,000 in 1991.2 In South Korea, Yang and colleagues3
reported a significant 23-fold increase (0.07e1.68 per
100,000) in UC between 1986 and 2005. In Hong Kong, the
mean annual age-specific incidence of UC has increased six-
fold from 1986 to 2006 (from 0.3 to 1.8 per 100,000).4 A
westernized environment and lifestyle are considered to be
primary causative factors of the upward increment of IBS
frequency in Asia.1 Preliminary observations also indicate that
IBDpatients inAsia seem to have less familial clustering,milder
disease manifestation, lower rates of surgery, and lower rates of
UC-related colorectal cancer compared with the West.1
In Taiwan, research into the cause, prevention, or manage-
ment of IBD is extremely rare. In an abstract based on data from
the Taiwan National Health Insurance Research Database, the
annual incidence rates of UC progressively increased from 0.54
in 1998 to 0.94 in 2008 per 100,000, and theUC prevalence rates
significantly increased from 0.72 in 1998 to 7.05 in 2008 per
100,000.5 Using the similar database, Lin and colleagues6
demonstrated that Taiwanese women with UC were at
a higher risk of having preterm and low birth weight babies
comparedwithmothers unaffected by the disease. Nevertheless,
whether the clinical presentation and health histories of UC
patients in Taiwan share similar or have different clinical
features with other Asian or Western countries remains unclear.
In this issue, Wei and colleagues7 have presented a compre-
hensive review summarizing the clinical data from a large series
of UC patients (n ¼ 406) diagnosed at the National Taiwan
UniversityHospital from1988 to 2008. This studymay be one of
the largest Chinese patient series to be reported in the English-
language medical literature. The authors found that the
number of UC patients gradually increased in their hospital
during the investigating period. These patients usually presented
with bloody stool (77.3%) or with total colonic involvement
(41.0%). Also, UC in Taiwan occurs slightly more frequently in
men than women (1.35:1), and it has the peak age of occurrence1726-4901/$ - see front matter Copyright  2012 Elsevier Taiwan LLC and the C
doi:10.1016/j.jcma.2012.04.011at around 36 years. Overall, these findings were similar to those
results obtained from studies in other Asian countries.8,9
IBD can result from both genetic influences and environ-
mental factors. In this study, the authors found 1.5% of their
patients had a family history of UC, similar to family history
prevalence in Korea (1.8%), and much lower than that prev-
alences in Western countries (5%e8%).10 This finding could
partly arise from the lower general IBD incidence/prevalence
in Asia countries than in Western countries. Despite these
numbers, the result of our study still suggests that family
clustering of IBD cases, although less common, is still
observed in Asian populations.
Regarding disease control and progression the current study
confirmed the belief that most UC patients in Asia, including
Taiwan, have amilder formUC, which can usually be controlled
with 5-aminosalicylic acid alone (72.4%). Nevertheless, the
authors demonstrated that someUCpatients in Taiwanwere still
steroid-dependent (4%), while others might even need immu-
nosuppressive agents or surgery (5.5%) to control the disease
activity or UC-related complications. Dysplasia and colorectal
cancer (CRC) are recognized as the long-term complications of
UC. In a meta-analysis generated from data of Western coun-
tries, the CRC rates are 1.6% at 10 years, 8.3% at 20 years, and
18.4% at 30 years.1 In Asia, the prevalence of CRC in UC
patients in the Asia-Pacific region appears to be much lower,
ranging from 0.3%e1.8%.9 In the current series, six UC patients
(1.5%, primarily female) developed CRC at least 10 years after
UC diagnosis, which seemed to be at the higher range of the
Asian data and almost comparable with the occurrence rates of
dysplasia/CRC in UC from Western countries. This unusual
observation deserves for further investigation. With the poten-
tial increasing numbers of UC cases in Taiwan, colonoscopic
surveillance with biopsy may be warranted for every UC
patients after 8 years of diagnosis. Extraintestinal manifesta-
tions (4.5%) can also be observed inUC patients in Taiwan, with
primary sclerosing cholangitis most commonly observed
(n ¼ 6; 1.5%). This finding is consistent with the proposition
that UC-associated PSC is less prevalent in the Asia-Pacific
region (0%e2.2%) when compared to the West (2%e7%).9
The current study results presented by Wei and colleagues7
are valuable in showing us the burgeoning trend and
frequency of UC in Taiwan. Through the study, we obtain an
overview of the current clinical status and natural history of UC
in Taiwan. UC is not hard to diagnose, and conventional therapyhinese Medical Association. All rights reserved.
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patients in Taiwan. Nevertheless, various unanswered questions
and challenges in the pathogenesis, diagnosis and management
of UC in Taiwan or even Asia still remain. For example, what is
the exact cause for the increased incidence and prevalence of
IBD in Taiwan/Asia? Is there any genetic marker characterized
the IBD patients in Taiwan/Asia? Is there any change in the
intestinal microbiota pattern among the IBD patients in Taiwan/
Asia? What is the optimal surveillance protocol for the IBD
patients in Taiwan/Asia? What is the optimal dose of steroid or
immunosuppressive agents for UC patients in Taiwan/Asia?
What is the better time to switch to biologic agents or even
colectomy in Taiwan/Asia? Therefore, it is hoped that
researchers in this area would undertake further studies in this
rapid evolving field, where such efforts can ultimately lead to
enhanced care for the management of our potentially rising UC
patients.
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